Navigation Links
CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
Date:8/25/2009

er individualize patient care.

"Our decision to develop Corus CAD was derived from many physician interactions in which they stressed the importance of and current challenges with effectively assessing obstructive CAD in patients with stable chest pain," said Levison. "We envision that a non-invasive, objective, easy-to-use test such as Corus CAD will empower physicians to more confidently identify which of these patients may have obstructive CAD."

About Corus CAD

Corus CAD is a clinically validated genomic test that integrates the expression levels of 23 genes and other patient characteristics to assess obstructive CAD. The test is intended to be used in an outpatient setting with clinically stable, non-diabetic patients who present with chest pain or who have a high risk of coronary artery disease, but without previously diagnosed myocardial infarction (heart attack) or prior revascularization procedure. Corus CAD is convenient and safe, and only requires a standard blood draw procedure. The test yields an objective result delivered to the physician in the form of a numeric score that quantifies the likelihood that a patient with stable chest pain has obstructive CAD.

Clinical Data

CardioDx designed a rigorous scientific plan and a prospective, nationwide, multi-center clinical study, PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary Tree, www.clinicaltrials.gov) to develop and validate Corus CAD. The PREDICT study sought to determine whether a gene expression test could be developed to identify obstructive CAD in patients with stable chest pain. The company has collected more than 2,800 patient samples in PREDICT from more than 40 clinical sites in the United States as of April 2009. Trial results and the Corus CAD validation data are expected to be presented toward the end of 2009.

About Obstructive CAD

Cardiovascular di
'/>"/>

SOURCE CardioDx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... data demonstrates that flibanserin, a novel, non-hormonal medicine being ... dysfunction, Hypoactive Sexual Desire Disorder (HSDD), does not impair ... when taken at bedtime. The data was presented at ... (SMSNA) 20th Annual Fall Scientific Meeting in ... accepted this study as a late breaking abstract for ...
(Date:11/22/2014)... Nov. 21, 2014 Statistics released from a ... driving increase astronomically during the holidays, beginning with Thanksgiving ... cities. The data, highlighted in ... as part of their annual Sober Days ... picture of high-risk drinking and increased rates of DUI ...
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
Breaking Medicine Technology:Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3Alarming Stats Show Holiday Drinking an Issue for Many 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... Sept. 8 Silence Therapeutics plc (AIM: SLN) ("Silence" ... patents by the United States Patent and Trademark Office ... RNA (siRNA) sequences against the validated cancer targets epidermal ... growth factor receptor 1 (VEGFR1).  EGFR-RP and VEGFR1 have ...
... -- POINT RICHMOND, Calif., Sept. 7 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Medicine Technology:Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics 2Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics 3Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics 4Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 2Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 3Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 4Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 5Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 6Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 7
(Date:11/24/2014)... November 24, 2014 Dr. Michael Kettel ... Center, recently appeared on NBC to discuss egg freezing as ... has been trending in the news recently, with new company ... for women. , “[The companies] see it as ... on a career hot path.” Says Dr. Kettel. , Up ...
(Date:11/23/2014)... For the coming special Friday, Tidebuy, a famous ... promotion for many products, especially the beautiful colored wedding ... choice with amazing discounts, up to 90% off. Don’t ... is easy to buy colored wedding dresses in different ... also famous for delicate craftsmanship, elegant style and perfect ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Nearly ... heart attacks, strokes, deep vein thrombosis and other ... a federal multidistrict litigation (MDL) underway in the ... , Court documents updated on November 17th ... (JPML) show the filing of 259 lawsuits against ...
(Date:11/23/2014)... November 23, 2014 This evaluation ... as its significance, programs and manufacturing technological innovation. ... suppliers major market gamers in information. In this ... specifications, prospective, manufacturing value, and 2009-2014 market shares ... evaluation symbolizes the globally and Chinese suppliers finish ...
(Date:11/23/2014)... AngelWeddingDress.com has recently updated its online store, ... dresses. “If you are looking for gorgeous beach wedding ... possible. Here you can enjoy 70% off discounts and ... a big marriage ceremony is the most important dream ... dress is uppermost priority. Ophelia, one of customers, said, ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2
... Texas, Nov. 12 A Fort Worth family has been ... negligence case resulting from improper treatment to a newborn child ... Dallas County by the child,s mother, Tiffany Martinez, and alleged ... to diagnose the hip dysplasia [dislocation] and failed to provide ...
... Mesa Laboratories, Inc. (Nasdaq: MLAB ) today announced ... dividend of $.11 per share of common stock, up from ... payable December 15, 2009, to shareholders of record on November ... has maintained strong cash positions and has continued to build ...
... in day-to-day actions , THURSDAY, Nov. 12 (HealthDay News) -- ... complex decisions, from what to make for dinner to whether ... "Humans make much more complex decisions than other animals -- ... to start a family -- and we wanted to understand ...
... research published in the November issue of the ... that African-American patients with colorectal cancer are more likely ... likely to undergo surgical procedures compared with Caucasians, suggesting ... reduce differences in colorectal cancer outcomes for African-Americans. ...
... ... be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain ... that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53 -- ... ...
... ... lecture at global Alzheimer,s conference on the groundbreaking topic of Alzheimer,s prevention. ... Naples, FL (PRWEB) ... First International Conference on Alzheimer’s Disease and Advanced Neurotechnologies on the topic of Alzheimer,s ...
Cached Medicine News:Health News:Dallas County Jury Finds in Favor of Family in Medical Malpractice Suit 2Health News:What's for Dinner? Brain Chemical Helps People Decide 2Health News:African-Americans with colorectal cancer have poorer outcomes, lower survival rates 2Health News:Cornell Researchers Identify a Weak Link in Cancer Cell Armor 2Health News: Integrative Neurologist Breaks Ground in Alzheimer's Prevention 2
... 1/3 hp. 0-8 scfm/0-29.8 in.hg.@sea level. Incredibly ... to 4 collection canister systems at one ... changes during the procedure. Standard canister set-up ... filters not included). UL, c-UL and CE ...
... is a new term being used today to describe ... liquid fill that may have been used in silicone ... science, this is not new technology cohesive is ... the sticking together nature of the gel. All of ...
This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
... designed to enhance the chin contour, this chin ... a high-profile central chin projection. Symmetrical Chin ... this implant provides a high central projection, as ... Cleft Chin Implants - Designed with a unique ...
Medicine Products: